verapamil has been researched along with dmp 728 in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 2 (100.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Aungst, BJ; Saitoh, H | 1 |
Aljada, A; Dandona, P; Khurana, U; Love, J; Mousa, S; Thusu, K | 1 |
2 other study(ies) available for verapamil and dmp 728
Article | Year |
---|---|
Intestinal absorption barriers and transport mechanisms, including secretory transport, for a cyclic peptide, fibrinogen antagonist.
Topics: Animals; Antibodies, Monoclonal; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Dose-Response Relationship, Drug; Drug Interactions; Fibrinogen; Intestinal Absorption; Intestinal Mucosa; Male; Mesylates; Peptides, Cyclic; Platelet Aggregation Inhibitors; Protons; Rats; Rats, Sprague-Dawley; Verapamil | 1996 |
Calcium, calmodulin and protein kinase C dependence of platelet shape change.
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Binding Sites; Blood Platelets; Calcium; Calcium Channel Blockers; Calmodulin; Cell Size; Chelating Agents; Edetic Acid; Gallic Acid; Humans; Intracellular Fluid; Mesylates; Peptides, Cyclic; Platelet Activation; Platelet Aggregation Inhibitors; Prostaglandin Endoperoxides, Synthetic; Protein Kinase C; Thromboxane A2; Vasoconstrictor Agents; Verapamil | 1996 |